home · filing · 0001558370-25-000639
8-K filed February 5, 2025, 6:59 PM ET
ticker TECH
CIK 0000842023
earnings
confidence high
sentiment positive
materiality 0.65
Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend
BIO-TECHNE Corp
2025-Q2 EPS
reported $0.42
vs consensus $0.51
▼ miss
(-17.5%)
Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.
Protein Sciences segment grew 8% organic; Diagnostics & Spatial Biology grew 12% organic.
Declared $0.08 per share quarterly dividend, payable Feb 28, 2025 to holders of record Feb 17, 2025.
Dr. Amy Herr appointed independent director effective Feb 1, 2025; serves on Science & Technology Committee.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Amy Herr
Independent Director
Effective 2025-02-01
Filed February 5, 2025, 6:59 PM ET
On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Amy Herr was appointed as Independent Director at BIO-TECHNE Corp.
Action appointed
Role Independent Director
Exact text from the filing
On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.
View on SEC.gov
Source: SEC EDGAR
accession 0001558370-25-000639
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.